EYE NEON
Research type
Research Study
Full title
Prevalence of subclinical Non-Exudative choroidal neovascularisation and its contribution to prediction of exudatiON in fellow eyes with unilateral exudative AMD (EYE-NEON)
IRAS ID
290536
Contact name
Sobha Sivaprasad
Contact email
Sponsor organisation
Moorfields Eye Hospital NHS Foundation Trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Patients with wet age-related macular degeneration (wAMD) in one eye are at risk of developing wAMD in the second "normal" eye (fellow eye) as well. This risk increases yearly and one of the factors among these is presence of inactive wet AMD in the fellow eye (study eye). At present, there is not sufficient knowledge to inform patients how the presence of this inactive disease in the “normal eye" would affect the risk for conversion to wet AMD, which makes counselling patients and planning difficult.
This study will therefore collect coded (pseudoanonymised) retinal images from scans and markers on these retinal image scans will be looked at. The risk of conversion in the "normal eye" to wet AMD will be calculated.
The study will be divided into 2 parts:
1.Prospective: Patients with a new diagnosis of wAMD and started on antiVEGF will consent for the prospective part of the study. Optical Coherence Tomography (OCT) and Optical Coherence Tomography Angiography (OCTA) will be used to image the study eye at a baseline visit and then at 1 and 2 years later to identify and study progress of Non-exudative Choroidal Neovascularization (neCNV) to predict increased risk of conversion of inactive wAMD to wAMD.
2. Retrospective: All patients who have started on antiVEGF treatment in one eye with wAMD in the last 12-15 months and the study eye that meet the inclusion and exclusion criteria will also be included in the study for retrospective data collection. Images from scans taken as per standard care will be collected for the study at baseline and year 1 and 2.The study will run at approximately 25 sites across the UK. Patients will be in the study for 2 years and the study will run for 48 months.
REC name
London - City & East Research Ethics Committee
REC reference
20/PR/0897
Date of REC Opinion
14 Jan 2021
REC opinion
Favourable Opinion